a-LOW-se-tron
REMS
Severe diarrhea-predominant irritable bowel syndrome (IBS) in women who have chronic symptoms (≥6 mo), no other GI pathology, and have had no response to conventional therapy.
Contraindicated in:
Use Cautiously in:
GI: constipation
Drug-drug:
Therapeutic Classification: anti irritable bowel syndrome agents
Pharmacologic Classification: five ht3 antagonists
Absorption: 50–60% absorbed following oral administration.
Distribution: Widely distributed to tissues.
Half-Life: 1.5 hr.
(pain/discomfort, diarrhea)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | within 1–2 wk | up to 6 wk | 1 wk‡ |
‡Following discontinuation.
Caution patient to stop taking alosetron and report constipation or signs of ischemic colitis to health care professional immediately. Immediately contact health care professional again if constipation does not resolve after discontinuation of alosetron. Alosetron should be resumed only after constipation has resolved and on the advice of their health care professional. Treatment with alosetron should not be resumed in patients who develop ischemic colitis.
NDC Code